BEAM Beam Therapeutics Inc

Price (delayed)

$42.51

Market cap

$2.99B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.57

Enterprise value

$2.83B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a ...

Highlights
BEAM's equity has surged by 96% year-on-year
The EPS is up by 46% year-on-year and by 38% since the previous quarter
BEAM's quick ratio is up by 11% year-on-year but it is down by 6% since the previous quarter
The debt has grown by 10% YoY

Key stats

What are the main financial stats of BEAM
Market
Shares outstanding
70.27M
Market cap
$2.99B
Enterprise value
$2.83B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.52
Price to sales (P/S)
48.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.92
Earnings
Revenue
$60.27M
EBIT
-$238.29M
EBITDA
-$228.93M
Free cash flow
$148.21M
Per share
EPS
-$3.57
Free cash flow per share
$2.16
Book value per share
$12.06
Revenue per share
$0.88
TBVPS
$21.15
Balance sheet
Total assets
$1.45B
Total liabilities
$624.33M
Debt
$150.13M
Equity
$829.07M
Working capital
$1.02B
Liquidity
Debt to equity
0.18
Current ratio
5.66
Quick ratio
5.65
Net debt/EBITDA
0.7
Margins
EBITDA margin
-379.8%
Gross margin
100%
Net margin
-395.4%
Operating margin
-445.2%
Efficiency
Return on assets
-19.1%
Return on equity
-31.2%
Return on invested capital
-30.1%
Return on capital employed
-19.3%
Return on sales
-395.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BEAM stock price

How has the Beam Therapeutics stock price performed over time
Intraday
2.26%
1 week
18.84%
1 month
35.21%
1 year
-54.78%
YTD
-46.66%
QTD
-25.81%

Financial performance

How have Beam Therapeutics's revenue and profit performed over time
Revenue
$60.27M
Gross profit
$60.27M
Operating income
-$268.32M
Net income
-$238.29M
Gross margin
100%
Net margin
-395.4%
The net margin has soared by 100% YoY and by 45% from the previous quarter
Beam Therapeutics's operating margin has surged by 100% YoY and by 41% QoQ
The net income has increased by 36% since the previous quarter and by 35% year-on-year
Beam Therapeutics's operating income has increased by 32% QoQ and by 12% YoY

Growth

What is Beam Therapeutics's growth rate over time

Valuation

What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
3.52
P/S
48.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
46.92
The EPS is up by 46% year-on-year and by 38% since the previous quarter
BEAM's equity has surged by 96% year-on-year
The price to book (P/B) is 57% lower than the last 4 quarters average of 8.2
BEAM's price to sales (P/S) is 100% lower than its last 4 quarters average of 85296.9
Beam Therapeutics's revenue has increased by 16% from the previous quarter

Efficiency

How efficient is Beam Therapeutics business performance
The return on sales has surged by 100% year-on-year and by 45% since the previous quarter
The company's return on assets has surged by 78% YoY and by 46% QoQ
The ROE has soared by 77% YoY and by 44% QoQ
BEAM's ROIC has soared by 76% YoY and by 45% QoQ

Dividends

What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAM.

Financial health

How did Beam Therapeutics financials performed over time
The total assets is 133% more than the total liabilities
Beam Therapeutics's total liabilities has surged by 131% YoY but it has decreased by 3.6% QoQ
The total assets has soared by 110% YoY
The debt is 82% less than the equity
BEAM's equity has surged by 96% year-on-year
The company's debt to equity fell by 44% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.